Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Invested Capital (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of Return on Invested Capital data on record, last reported at 0.49% in Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 60.0% year-over-year to 0.49%; the TTM value through Dec 2025 reached 0.49%, down 60.0%, while the annual FY2025 figure was 0.43%, 57.0% down from the prior year.
  • Return on Invested Capital reached 0.49% in Q4 2025 per TRDA's latest filing, down from 0.33% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.25% in Q2 2024 and bottomed at 0.49% in Q4 2025.
  • Average Return on Invested Capital over 3 years is 0.12%, with a median of 0.01% recorded in 2023.
  • Peak YoY movement for Return on Invested Capital: soared 68bps in 2024, then tumbled -60bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.01% in 2023, then surged by 1420bps to 0.11% in 2024, then tumbled by -551bps to 0.49% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.49% in Q4 2025, 0.33% in Q3 2025, and 0.23% in Q2 2025.